Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1532-1541

  De Preter, Katleen ^a   Vermeulen, Joëlle ^a   Brors, Benedikt ^b   Delattre, Olivier ^c   Eggert, Angelika ^d   Fischer, Matthias ^e   Janoueix Lerosey, Isabelle ^c   Lavarino, Cinzia ^f   Maris, John M ^g   Mora, Jaume ^f   Nakagawara, Akira ^h   Oberthuer, André ^e   Ohira, Miki ^h   Schleiermacher, Gudrun ^c   Schramm, Alexander ^d   Schulte, Johannes H ^d   Wang, Qun ^g   Westermann, Frank ^b   Speleman, Frank ^a   Vandesompele, Jo ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f HOSPITAL SANT JOAN DE DÉU   (Spain)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; CANCER DIAGNOSIS; CORRELATION ANALYSIS; GENE EXPRESSION PROFILING; GENETIC SELECTION; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIGENE FAMILY; NEUROBLASTOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; VALIDATION PROCESS;

CHILD; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIERS ESTIMATE; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77649159750     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2607     Document Type: Article

References (29)

1. Brodeur GM, Fong CT, Morita M, Griffith R, Hayes FA, Seeger RC. Molecular analysis and clinical significance of N-myc amplification and chromosome 1p monosomy in human neuroblastomas. Prog Clin Biol Res 1988;271:3-15.
2. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
3. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
4. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 1971; 27:374-8.
5. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231-5.
6. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005;17:7-13.
7. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72.
8. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
9. Simon R. Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer 2003; 89:1599-604.
10. Tinker AV, Boussioutas A, Bowtell DD. The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 2006;9:333-9.
11. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365:488-92.
12. Berwanger B, Hartmann O, Bergmann E, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002;2:377-86.
13. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-8.
14. Ohira M, Oba S, Nakamura Y, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005;7:337-50.
15. Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66:6050-62.
16. Bussey KJ, Kane D, Sunshine M, et al. MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol 2003;4:R27.
17. Ruschhaupt M, Huber W, Poustka A, Mansmann U. A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol 2004;3:Article37.
18. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-26.
19. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
20. Yamanaka Y, Hamazaki Y, Sato Y, et al. Maturational sequence of neuroblastoma revealed by molecular analysis on cDNA microarrays. Int J Oncol 2002;21:803-7.
21. Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64: 6883-91.
22. Takita J, Ishii M, Tsutsumi S, et al. Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer 2004;40:120-32.
23. Ohira M, Morohashi A, Inuzuka H, et al. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 2003;22: 5525-36.
24. Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, Yokoyama T. Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int 2004;20:33-8.
25. Asgharzadeh S, Pique-Regi R, Sposto R, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006;98: 1193-203.
26. Abel F, Sjoberg RM, Nilsson S, Kogner P, Martinsson T. Imbalance of the mitochondrial pro- and anti-apoptotic mediators in neuroblastoma tumours with unfavourable biology. Eur J Cancer 2005; 41:635-46.
27. Chen QR, Song YK, Wei JS, et al. An integrated cross-platform prognosis study on neuroblastoma patients. Genomics 2008;92: 195-203.
28. Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. BMC Cancer 2007;7:89.
29. Vermeulen J, De Preter K, Naranjo A, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10: 663-71.